Kymera Therapeutics rises after positive data for eczema drug

Shares of Kymera Therapeutics KYMR.O rise 5.6% to $70.32 premarket

KYMR says its experimental oral treatment for eczema eased symptoms and itching in a small early-stage study, while also helping patients who had asthma or hay fever

The company tested the drug, KT-621, in 22 people with moderate-to-severe atopic dermatitis, with patients seeing their overall eczema severity scores fall by an average of 63%, and about a 40% drop in peak itching

Kymera says KT-621 was well tolerated, with no serious side effects, no treatment-related safety issues and no cases of eye inflammation that have been seen with some other eczema drugs

KYMR stock was up 65.6% YTD